SW480 Transfection Kit (Colon Carcinoma, CCL228)


Kit Size VolumePricePay with CC, PO, or PaypalAdd to Cart
0.5 ml (Catalog #6920)$419.00
1.5 ml (Catalog #6921)$839.00
1.5 ml CRISPR (Catalog #2198)$839.00
8.0 ml (Catalog #6922)$2,217.00
SKU: SW480 Category:


Purchase Orders: Click “Add to Cart” button to order, then email PO to orders@altogen.com.

Product Availability: In Stock.

Transfection Reagent for SW480 Cells (Colon Adenocarcinoma Cells, CCL-228)

  • A biodegradable polymer based transfection agent – once inside the cell, the polymer degrades into smaller less toxic components reducing cell toxicity, facilitating release of the transgene, and improving transfection efficiency
  • Effective transfection under conditions of up to 40% serum
  • Gentle enough to be used for single cell analysis
  • Download in vitro SW480 transfection protocol: [PDF]
  • Download SW480 CRISPR/Cas9 transfection protocol: [PDF]
  • Download PowerPoint presentation for SW480 cells transfection kit: [PPT]
  • UPC/GTIN/EAN: 860002089705
  • Brand: ALTOGEN®, developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 82% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Product Description:

Pre-optimized transfection kit for high transfection efficiency of SW480 cell line, a human colorectal adenocarcinoma cells. Transfection reagent is compatible with DNA and RNA transfection.

Transfection Protocol and SDS:

Download Altogen Biosystems SW 480 Transfection Protocol: [PDF]

Download SDS: [PDF]

SW480 Cell Line:

Colorectal cancer is the second primary cause of cancer-related deaths in men, accounting for nearly 50,000 fatalities annually in the United States, as per the American Cancer Society (ACS). Colorectal cancer cell lines are extensively employed in preclinical colon cancer research and represent accurate molecular models of primary carcinomas. The SW480 cell line was established from a Dukes type B tumor in the colon of a 50-year-old Caucasian male patient with colorectal adenocarcinoma. The cells exhibit an epithelial morphology, and are susceptible to human immunodeficiency virus 1. Also, The SW480 cell line is negative for colon antigen 3 and colon-specific antigen-p and produces granulocyte-macrophage colony-stimulating factor. This cell line is positive for keratin by immunoperoxidase staining. SW480 display elevated levels of p53 protein, and positively expresses c-myc, K-ras, H-ras, N-ras, sis, myb, and fos oncogenes. SW480 cells have a mutation in the 12 codon of the ras p.o.gene, and therefore can be used in PCR assays of mutation for this codon. This cell line is widely used in biomedical research related to the search for treatments for colon cancer. Altogen Biosystems provides polymer-based transfection kits for the SW480 cell line.

SW480 cells are a human colorectal adenocarcinoma cell line that was isolated from a primary tumor of a 50-year-old male patient. The cell line was established in 1977 and has been widely used in cancer research as a model for colorectal cancer. SW480 cells have a typical epithelial morphology and can be cultured as adherent monolayers in standard tissue culture conditions. They are known to have a high proliferation rate and are commonly used to study cell signaling pathways, tumor invasion and metastasis, drug resistance, and other aspects of cancer biology. SW480 cells are often used as a model system for studying the molecular mechanisms underlying colorectal cancer, which is one of the most common cancers worldwide. Researchers use SW480 cells to investigate the genetic and molecular changes that occur during cancer development, and to test the efficacy of novel cancer therapies. SW480 cells are also used in drug screening assays to identify potential anti-cancer drugs. The cells have been shown to be sensitive to a wide range of chemotherapeutic agents, including 5-fluorouracil, oxaliplatin, and irinotecan, which are commonly used in the treatment of colorectal cancer.

SW480 cell line mutations:

KRAS 3845 37 12 25398284 25398284 Missense_Mutation SNP C A
TP53 7157 37 17 7577120 7577120 Missense_Mutation SNP C T
RIMS2 9699 37 8 104898096 104898096 Silent SNP T G
APC 324 37 5 112175303 112175303 Nonsense_Mutation SNP C T
UNC13C 440279 37 15 54306737 54306737 Missense_Mutation SNP T G
NEB 4703 37 2 152432838 152432838 Missense_Mutation SNP G A
NCAM1 4684 37 11 113105855 113105855 Silent SNP C T
USH2A 7399 37 1 216040469 216040469 Missense_Mutation SNP C T
OR2AK2 391191 37 1 248129496 248129496 Missense_Mutation SNP C T
GIMAP4 55303 37 7 150269429 150269429 Missense_Mutation SNP G A
CYP11B1 1584 37 8 143960555 143960555 Silent SNP G A


SW480 Transfection Kit

Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into SW480 cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).


Figure 2. Protein expression of Lamin A/C in SW480 cells. DNA plasmid expressing Lamin A/C or siRNA targeting Lamin A/C were transfected into SW480 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

Selected in vivo transfection product citations (ALTOGEN® IN VIVO Transfection Kits used in the following publications):

  • 2008 454(7203):523-7. Innate immunity induced by composition-dependent RIG-I …Saito et al [PDF]
  • Am J Pathology. 2010 177(4):1870-80. Role of ocular complement factor H in a murine model … Lyzogubov et al [PDF]
  • Nature Biotechnology. 2011 29(4):341-5. Delivery of siRNA to the mouse brain by … Alvarez-Erviti et al [PDF]
  • Cancer Research. 2011 71(15):5144-53. Inhibition of miR-193a expression by… Iliopoulos et al [PDF]
  • 2010 16(11):2108-19. RNase L releases a small RNA from HCV RNA that refolds … Malathi et al [PDF]

Altogen Biosystems manufacturers over 100 pre-optimized in vitro transfection kits for cancer cell lines and primary cells, elecroporation products, and  tissue-targeted in vivo delivery reagents for life science research. Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of protein, DNA, mRNA, shRNA and siRNA molecules. Read more about transfection technology at Altogen’s Transfection Resource. Altogen Labs provides safety and efficacy preclinical research services. GLP-compliant studies for IND applications, and drug development, including over 90 in-house validated xenograft models, safety toxicology, etc (visit AltogenLabs.com).

SW480 Transfection Kit

Volume Options:

  • 0.5 ml (Catalog #6920)
  • 1.5 ml (Catalog #6921)
  • 1.5 ml CRISPR (Catalog #2198)
  • 8.0 ml (Catalog #6922)

Purchase Orders: Click “Add to Cart” button to order, then email PO to orders@altogen.com.

Product Availability: In Stock.

Additional information

Weight 1 lbs
Dimensions 4 × 3 × 0.2 in
Kit Size (Volume)

0.5 ml (Catalog #6920), 1.5 ml (Catalog #6921), 1.5 ml CRISPR (Catalog #2198), 8.0 ml (Catalog #6922)